TLXのPER（株価収益率）は？

TELIX PHARMACEUTICALS LIMITED（TLX）は現在PER 67.12倍で取引されています。

TLXのROE（自己資本利益率）は？

TELIX PHARMACEUTICALS LIMITEDのROEは-1.72%です。

TLXの配当利回りは？

TELIX PHARMACEUTICALS LIMITEDの配当利回りは0.00%です。

TLXの品質スコア（Quality Score）は？

当社のAIはTLXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

TLXは今が買い時ですか？

当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

TLXはどのセクターに属しますか？

TELIX PHARMACEUTICALS LIMITEDはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

TLX (NASDAQ) 株価分析 | TELIX PHARMACEUTICALS LIMITED

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2025-12-31)

TLX AI Analysis Summary

Our AI summary for TLX: TELIX PHARMACEUTICALS LIMITED (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 67.12, ROE of -1.72%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TLX

TELIX PHARMACEUTICALS LIMITED

US:NASDAQ STOCK Healthcare >> Biotechnology News 84

USD 9.89

-0.17 (-1.69%) Day Change

Watchlist Portfolio Compare Chart

67.12

P/E

0.67

D/E

-1.7%

ROE

-0.6%

ROA

0.00%

Div Yield

0.19

PEG

TELIX PHARMACEUTICALS LIMITED
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 9.89 Price -0.17 (-1.69%) Day Change	NEWS SCORE: 84

TLX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	84
Magic Formula Rank by ROA	2696
Magic Formula Rank by ROE	2696
Magic Formula Rank by ROIC	2308
Price	9.89
PBV / Sector	5.38 / 5.20
Earning Per Share	-0.03

PE / Sector	67.12 / 19.97
PEG or PE/Growth / Sector	0.19 / 1.22 GREAT
Average 1M Daily Value	1.36 M GREAT
Average 1W Daily Value	0.79 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-0.89 / 98.71
NPM Average (%) / Sector	-14.62 / -1,721.76
NPM Change Average (%) / Sector	99.72 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-0.60 / 27.02
ROA Average (%) / Sector	-9.19 / -368.17
ROA Change Average (%) / Sector	-23.31 / 5,404.12
ROE (%) / Sector	-1.72 / 3.47
ROE Average (%) / Sector	-29.88 / 6.51
ROE Change Average (%) / Sector	-23.73 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 08:00:35
Symbol	TLX
Name	TELIX PHARMACEUTICALS LIMITED
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	338.78 M
Par Value	N/A
Calculated From	YearEnd
Sign	N/A
Market Cap (M.USD) / Sector Average	3,350.51 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 55 Flemington Road, North Melbourne, VIC, Australia, 3051

Phone: 61 3 9093 3855

Website: https://telixpharma.com

Employees: 1,120

Sector: Healthcare >> Biotechnology

Description: Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.